Evidence map›Paper›PMID 37591971›Full record

ArticleScientific reports2023

Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3.

Pragya Rampuria, Lidia Mosyak, Adam R Root, Kristine Svenson, Michael J Agostino, Edward R LaVallie

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Immunotherapy for precision medicine in colorectal cancer.Expert review of precision medicine and drug development · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Pragya Rampuria *Biomedicine Design, Pfizer Inc., 610 Main St., Cambridge, MA, 02139, USA. pragya.rampuria@pfizer.com.
Lidia Mosyak *Biomedicine Design, Pfizer Inc., 610 Main St., Cambridge, MA, 02139, USA. lidia.mosyak@pfizer.com.
Adam R RootGenerate Biomedicines Inc, Cambridge, MA, USA.
Kristine SvensonBiomedicine Design, Pfizer Inc., 610 Main St., Cambridge, MA, 02139, USA.
Michael J AgostinoPfizer Digital, Pfizer Inc., 1 Burtt Rd, Andover, MA, USA.
Edward R LaVallieBiomedicine Design, Pfizer Inc., 610 Main St., Cambridge, MA, 02139, USA.
Pfizer (United States) · USIntarcia Therapeutics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The intestinal epithelial receptor Guanylyl Cyclase C (GUCY2C) is a tumor-associated cell surface antigen expressed across gastrointestinal malignancies that can serve as an efficacious target for colorectal cancer immunotherapy. Here, we describe a yeast surface-display approach combined with an orthogonal peptide-based mapping strategy to identify the GUCY2C binding epitope of a novel anti-GUCY2CxCD3 bispecific antibody (BsAb) that recently advanced into the clinic for the treatment of cancer. The target epitope was localized to the N-terminal helix H2 of human GUCY2C, which enabled the determination of the crystal structure of the minimal GUCY2C epitope in complex with the anti-GUCY2C antibody domain. To understand if this minimal epitope covers the entire antibody binding region and to investigate the impact of epitope position on the antibody's activity, we further determined the structure of this interaction in the context of the full-length extracellular domain (ECD) of GUCY2C. We found that this epitope is positioned on the protruding membrane-distal helical region of GUCY2C and that its specific location on the surface of GUCY2C dictates the close spatial proximity of the two antigen arms in a diabody arrangement essential to the tumor killing activity of GUCY2CxCD3 BsAb.

Indexed as

Antibodies, BispecificReceptors, EnterotoxinT-LymphocytesEpitopesHumansRecognition, PsychologyAntibodies, BispecificEpitopesGUCY2C protein, humanReceptors, Enterotoxin

Identifiers

PMID37591971
PMCPMC10435522
OpenAlexW4385948266

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.